EGTX.ST

Egetis Therapeutics AB (publ) [EGTX.ST] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

EGTX.ST Stock Summary

Earnings have grown 156% per last year.

The Moving Average Convergence Divergence (MACD) for EGTX.ST recently turned positive (within last 10 days).

Top 10 Correlated Stocks

EGTX.ST

In the News

EGTX.ST Financial details

Company Rating

Market Cap

1.78B

Income

-326.6M

Revenue

57.5M

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

03 May 2024

P/E

-4.84

Forward P/E

PEG

-1.58

P/S

59.09

P/B

3.29

P/C

P/FCF

-6.02

Quick Ratio

1.39

Current Ratio

1.94

Debt / Equity

LT Debt / Equity

EPS (TTM)

-1.28

EPS next Y

EPS next Q

EPS this Y

29.59%

EPS next Y

EPS next 5Y

EPS last 5Y

3.29%

Revenue last 5Y

-6.95%

Revenue Q/Q

167.21%

EPS Q/Q

-14.29%

SMA20

SMA50

-16.67%

SMA100

66.67%

Inst Own

Inst Trans

ROA

-60%

ROE

-59%

ROC

-0.68%

Gross Margin

-559%

Oper. Margin

-1049%

Profit Margin

-1042%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

3.8-9.2

52W High

-36.33%

52W Low

+91%

RSI

Rel Volume

1.59

Avg Volume

380.62K

Volume

606.33K

Perf Week

9.98%

Perf Month

14.6%

Perf Quarter

45.43%

Perf Half Y

56.13%

Beta

1.295

Volatility

0.27%, 0.25%

Prev Close

-1.21%

Price

5.73

Change

4.37%

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 380.62K
Market Capitalization 1.78B
Employee 29
CEO Mr. Nicklas Westerholm
Headquarters Stockholm,SE
IPO Date 2011-04-07
Website https://www.egetis.com

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.